Latvia - Latvi - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - amlodipīns - tablete - 5 mg

Latvia - Latvi - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - sertralīns - apvalkotā tablete - 100 mg

Latvia - Latvi - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - tolterodīna tartrāts - apvalkotā tablete - 2 mg

Latvia - Latvi - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - tolterodīna tartrāts - apvalkotā tablete - 1 mg

Latvia - Latvi - Zāļu valsts aģentūra

viatris healthcare limited, ireland - ibuprofēns - suspensija iekšķīgai lietošanai - 40 mg/ml

Uni Eropa - Latvi - EMA (European Medicines Agency)

novartis europharm limited - eltrombopags - purpura, trombocitopēnija, idiopātija - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 un 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 un 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Latvia - Latvi - Zāļu valsts aģentūra

viatris healthcare limited, ireland - azelastini hydrochloridum, fluticasoni propionas - deguna aerosols, suspensija - 137 mikrogrami/50 mikrogrami devā

Uni Eropa - Latvi - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Uni Eropa - Latvi - EMA (European Medicines Agency)

accord healthcare s.l.u. - dabigatrāna eteksilāta mesilāts - venous thromboembolism; arthroplasty, replacement - antitrombotiskie līdzekļi - prevention of venous thromboembolic events.

Uni Eropa - Latvi - EMA (European Medicines Agency)

mylan pharmaceuticals limited - febuxostat - hyperuricemia; arthritis, gouty; gout - antigut preparāti - febuxostat mylan indicēts profilaksi un ārstēšanu pieaugušiem pacientiem veikta ķīmijterapija haematologic malignancies starpproduktu ar augsta riska audzēju līzes sindroms (tls) hyperuricaemia. febuxostat mylan ir indicēts, lai ārstētu hronisku hyperuricaemia apstākļos, kad urate uzklāšanas jau ir noticis (tai skaitā vēsturē, vai klātbūtne, tophus un/vai podagras artrīta). febuxostat mylan ir norādīts pieaugušie.